EPRSQ — Epirus Biopharmaceuticals Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Annual income statement for Epirus Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2011 December 31st | C2012 December 31st | R2013 December 31st | 2014 December 31st | 2015 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 8.18 | 12.6 | 0 | 0.004 | 0.701 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 0.576 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 50.8 | 55.4 | 14.5 | 39.3 | 52 |
Operating Profit | -42.7 | -42.8 | -14.5 | -39.3 | -51.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -43.5 | -44.8 | -20.8 | -41.9 | -52.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -42 | -44.3 | -20.8 | -41.8 | -52.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -42 | -44.3 | -20.8 | -41.8 | -52.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -42 | -44.3 | -20.8 | -41.8 | -52.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -25.9 | -22.3 | -88.3 | -6.81 | -2.32 |
Dividends per Share |